Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs) Award advances MediWound's DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today it has been selected to receive €16.25 million in blended funding from the European Innovation Council (EIC) through its accelerator program. Th ...

GOTHENBURG, Sweden, July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (Nasdaq: MDWD) (MediWound) through a definitive share purchase agreement in a private investment in public equity (PIPE). MediWound, a global leader in next-generation enzymatic therapeutics focused on non-surgical wound debridement, has a vision to improve the existing standards o ...

MediWound Ltd. (NASDAQ:MDWD) Q1 2024 Earnings Conference Call May 29, 2024 8:30 AM ET Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - EVP of Strategy & Corporate Development Daniel Ferry - IR, LifeSci Advisors Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - HC Wainwright Michael Okunewitch - Maxim Group Good day! And welcome to MediWound's First Quarter 2024 Earnings Call. Today's conference is being recorded. [Operator Instr ...

MediWound (MDWD) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.44 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 2.50%. A quarter ago, it was expected that this developer of treatments for burns and hard-to-heal wounds would post a loss of $0.23 per share when it actually produced a loss of $0.19, delivering a surprise of 17.39%. Over the ...

NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time YAVNE, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ende ...

YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2024 on Wednesday, May 29, 2024. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions. MediWound Contacts: | Hani Lu ...

MediWound (MDWD) shares soared 14.3% in the last trading session to close at $18.28. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.7% gain over the past four weeks.Last month, the company announced robust financial results for the full year and fourth quarter ended 2023. This might have been driving the share price rally.This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.40 ...

Company Highlights 14 successful clinical trials 120+ peer-reviewed publications Key approvals: FDA/EMA/JPN Significant commercial growth potential | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________________ to ____________________ OR ☐ SHELL COMPANY REPORT P ...

Revenue and Profitability - Revenue for 2023 was $19 million, with projected revenue of $24 million for 2024[1] - Total revenues for the twelve months ended December 31, 2023, decreased to $18.686 million from $26.496 million in 2022, representing a decline of approximately 29.9%[27] - Gross profit for the twelve months ended December 31, 2023, was $3.578 million, down from $13.165 million in 2022, indicating a decrease of about 72.8%[27] - Gross profit for Q4 2023 was $0.7 million, representing 13.5% of total revenue, down from 70.2% in Q4 2022[9] - Adjusted EBITDA for the year ended December 31, 2023, was a loss of $12.3 million, compared to a loss of $4.4 million in 2022[9] - Adjusted EBITDA for the twelve months ended December 31, 2023, was $(12.258) million, compared to $(4.443) million in 2022, indicating a decline of approximately 175.2%[33] Losses and Financial Position - Operating loss for the year ended December 31, 2023, was $15.3 million, compared to an $8.3 million loss in 2022[9] - The company reported an operating loss of $15.290 million for the twelve months ended December 31, 2023, compared to an operating loss of $8.345 million in 2022, indicating a worsening of approximately 83.5%[27] - Net loss for the year ended December 31, 2023, was $6.7 million, or $0.75 per share, compared to a net loss of $19.6 million, or $3.93 per share in 2022[9] - The net loss for the twelve months ended December 31, 2023, was $6.716 million, compared to a net loss of $19.599 million in 2022, reflecting an improvement of approximately 65.7%[27] - Cash and cash equivalents at the end of the period decreased to $11.866 million from $33.895 million at the end of 2022, a decline of about 65.0%[31] - Net cash used in operating activities for the twelve months ended December 31, 2023, was $10.465 million, compared to $11.885 million in 2022, a decrease of approximately 11.9%[29] Assets and Investments - Cash, restricted cash, and investments as of December 31, 2023, totaled $42.1 million, up from $34.1 million in 2022[10] - Total assets increased to $66.459 million as of December 31, 2023, from $50.016 million in 2022, representing a growth of approximately 32.7%[25] Research and Development - The company received $13 million in R&D funding from the U.S. Department of Defense for a new NexoBrid formulation[6] - Research and development expenses for the twelve months ended December 31, 2023, were $7.467 million, down from $10.181 million in 2022, a decrease of about 26.7%[27] - The Phase III study for EscharEx® is set to begin in the second half of 2024, with 216 patients to be treated globally[6] Manufacturing and Capacity - NexoBrid® was commercially launched in the U.S., Japan, and India, contributing to the revenue growth[3] - A new GMP-compliant manufacturing facility is projected to achieve a 6-fold increase in manufacturing capacity by 2025[3] Shareholder Information - The weighted average number of ordinary shares increased to 9,013,144 for the twelve months ended December 31, 2023, compared to 4,987,069 in 2022, an increase of about 80.6%[27]